```
FILE 'MEDLINE' ENTERED AT 12:32:27 ON 17 AUG 2003

FILE 'CAPLUS' ENTERED AT 12:32:27 ON 17 AUG 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:32:27 ON 17 AUG 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 12:32:27 ON 17 AUG 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

FILE 'SCISEARCH' ENTERED AT 12:32:27 ON 17 AUG 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'AGRICOLA' ENTERED AT 12:32:27 ON 17 AUG 2003

=> s bombesin
L1       21051 BOMBESIN

=> s dialklyated amino acid
L2           0 DIALKLYATED AMINO ACID

=> s aminoisobutyric acid
L3       11225 AMINOISOBUTYRIC ACID

=> s diethyl glycine
L4           7 DIETHYL GLYCINE

=> s di-n-propyl glycine
L5           7 DI-N-PROPYL GLYCINE

=> s l1 (w) (analog or derivative)
L6         592 L1 (W) (ANALOG OR DERIVATIVE)

=> s l1 (p) (analog or derivative)
L7        1962 L1 (P) (ANALOG OR DERIVATIVE)

=> s l7 (p) (l3 or l4 or l5)
L8           3 L7 (P) (L3 OR L4 OR L5)

=> duplicate remove l8
DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, EMBASE'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L8
L9            1 DUPLICATE REMOVE L8 (2 DUPLICATES REMOVED)

=> d l9 1 ibib abs

L9   ANSWER 1 OF 1     MEDLINE on STN                    DUPLICATE 1
ACCESSION NUMBER:   84057503     MEDLINE
DOCUMENT NUMBER:    84057503   PubMed ID: 6196181
TITLE:              Effects of porcine gastrin-releasing peptide on amylase
                    release, 2-deoxyglucose uptake, and alpha-aminoisobutyric
                    acid uptake in mouse pancreatic acini.
AUTHOR:             Iwamoto Y; Nakamura R; Akanuma Y
SOURCE:             ENDOCRINOLOGY, (1983 Dec) 113 (6) 2106-12.
                    Journal code: 0375040. ISSN: 0013-7227.
PUB. COUNTRY:       United States
DOCUMENT TYPE:      Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:           English
FILE SEGMENT:       Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH:        198401
ENTRY DATE:         Entered STN: 19900319
                    Last Updated on STN: 19980206
                    Entered Medline: 19840107
AB   The effects of synthetic porcine gastrin-releasing peptide (pGRP), a
     recently isolated gut hormone, were studied in isolated mouse pancreatic
     acini. pGRP was found to exert direct effects on amylase release,
     2-deoxyglucose ( [3H] 2DG) uptake, and alpha-  ***aminoisobutyric***
       ***acid***   (AIB) uptake.  The stimulatory effect of pGRP on amylase
     release was significant at 100 pM, and maximal at 1 nM.  Higher
     concentrations of pGRP exerted a smaller stimulatory effect on amylase
     release. pGRP also increased [3H]2DG uptake, exerting a detectable effect
```

at 300 pM, and a maximal effect at 30 nM. In contrast to its stimulatory effect on amylase release and [3H]2DG uptake, pGRP inhibited AIB uptake. A significant inhibitory effect on AIB uptake occurred at 100 pM, and a maximal inhibitory effect occurred at 3 nM. Dose-response curves of pGRP for amylase release and AIB uptake were found to be biphasic.
Bombesin was also found to stimulate amylase release with a biphasic dose-response curve in mouse acini. Both cholecystokinin (CCK) octapeptide and the cholinergic ***analog*** carbachol exerted similar effects in isolated mouse acini. However, the effects of pGRP were not inhibited by either dibutyryl cyclic guanosine 3',5'-monophosphate or atropine, whereas the effects of CCK octapeptide were inhibited by dibutyryl cyclic guanosine 3',5'-monophosphate and the effects of carbachol were inhibited by atropine. These results indicate that pGRP can mimic the biological effects of CCK and acetylcholine, but that its actions are probably mediated via a separate class of receptors in mouse acini.

```
=> s burman anand/au
L10             0 BURMAN ANAND/AU

=> s prasad sudhanand/au
L11            31 PRASAD SUDHANAND/AU

=> s jaggi manu/au
L12            26 JAGGI MANU/AU

=> s singh anu/au
L13            26 SINGH ANU/AU

=> s mathur archna/au
L14             6 MATHUR ARCHNA/AU

=> s maukherjee rama/au
L15             0 MAUKHERJEE RAMA/AU

=> s mukherjee rama/au
L16            64 MUKHERJEE RAMA/AU

=> s l11 or l12 or l13 or l14 or l16
L17           116 L11 OR L12 OR L13 OR L14 OR L16

=> d his

     (FILE 'HOME' ENTERED AT 12:32:03 ON 17 AUG 2003)

     FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
     12:32:27 ON 17 AUG 2003
L1          21051 S BOMBESIN
L2              0 S DIALKLYATED AMINO ACID
L3          11225 S AMINOISOBUTYRIC ACID
L4              7 S DIETHYL GLYCINE
L5              7 S DI-N-PROPYL GLYCINE
L6            592 S L1 (W) (ANALOG OR DERIVATIVE)
L7           1962 S L1 (P) (ANALOG OR DERIVATIVE)
L8              3 S L7 (P) (L3 OR L4 OR L5)
L9              1 DUPLICATE REMOVE L8 (2 DUPLICATES REMOVED)
L10             0 S BURMAN ANAND/AU
L11            31 S PRASAD SUDHANAND/AU
L12            26 S JAGGI MANU/AU
L13            26 S SINGH ANU/AU
L14             6 S MATHUR ARCHNA/AU
L15             0 S MAUKHERJEE RAMA/AU
L16            64 S MUKHERJEE RAMA/AU
L17           116 S L11 OR L12 OR L13 OR L14 OR L16

=> s l17 and l1
L18             4 L17 AND L1

=> duplicate remove l18
DUPLICATE PREFERENCE IS 'CAPLUS, BIOSIS'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L18
L19             4 DUPLICATE REMOVE L18 (0 DUPLICATES REMOVED)

=> d l19 1-4 ibib abs
```

L19 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:132[redacted] CAPLUS
DOCUMENT NUMBER: 138:186384
TITLE: Multivalent synthetic vaccine for cancer containing vasoactive intestinal peptide (VIP), ***bombesin*** , Substance P and epidermal growth factor (EGF) and related expression vector
INVENTOR(S): ***Mukherjee, Rama*** ; Rao, M. R. S.; Burman, Anand C.; Thomas, Becky; ***Prasad, Sudhanand*** ; Sengupta, Paromita
PATENT ASSIGNEE(S): Dabur Research Foundation, India; Cord, Janet, I.
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003013426	A2	20030220	WO 2002-US24561	20020802
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003082201	A1	20030501	US 2002-211994	20020802

PRIORITY APPLN. INFO.: US 2001-309975P P 20010803
AB Multivalent vaccine comprising peptides from vasoactive intestinal peptide, ***bombesin*** , Substance P and epidermal growth factor are described. In particular, disclosed is a fusion protein contg. all above four peptides or protein linked by Gly-Gly di-peptide. A method of constructing a multivalent gene for use in various expressions vectors and the protein recombinantly expressed in the prokaryotic expression systems are also described.

L19 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:636087 CAPLUS
DOCUMENT NUMBER: 135:190403
TITLE: Synthesis of ***bombesin*** peptide analogs and their uses in treatment of cancer
INVENTOR(S): Burman, Anand C.; Prasad, Sudhanan; ***Mukherjee,*** Rama*** ; ***Jaggi, Manu*** ; Singh, Anu T.; ***Mathur, Archna***
PATENT ASSIGNEE(S): Dabur Research Foundation, India
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001062777	A1	20010830	WO 2000-US20873	20000731
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000065053	A5	20010903	AU 2000-65053	20000731
EP 1261626	A1	20021204	EP 2000-952333	20000731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
US 2003105009	A1	20030605	US 2002-186226	20020628

PRIORITY APPLN. INFO.: IN 2000-DE147 A 20000224
WO 2000-US20873 W 20000731

US 2001-308273P P 20010727

OTHER SOURCE(S): MARPAT 1[redacted]190403

AB The invention discloses sequences of novel peptides that are antagonists to ***bombesin*** and ***bombesin*** like peptides and their uses in the treatment of cancer. The invention particularly relates to the design and synthesis of the novel peptides incorporating .alpha.,.alpha.-amino acids in a site specific manner. The invention also provides methods for the generation of these peptides, compns. contg. the peptides and the pharmacol. applications of these peptides esp. in the treatment and prevention of cancer.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:573679 CAPLUS

DOCUMENT NUMBER: 133:198647

TITLE: Antiangiogenic drugs

INVENTOR(S): ***Mukherjee, Rama*** ; ***Jaggi, Manu*** ; ***Prasad, Sudhanand*** ; Burman, Anand C.; Rajendran, Praveen; Mathur, Archana; Singh, Anu T.

PATENT ASSIGNEE(S): National Institute of Immunology, India; Dabur Research Foundation; Cord, Janet, I.

SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047221	A1	20000817	WO 2000-US3559	20000211
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6492330	B1	20021210	US 1999-248381	19990211
EP 1150700	A1	20011107	EP 2000-908603	20000211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.:

US 1999-248381	A1	19990211
IN 1996-DE1822	A	19960816
US 1996-727679	A2	19961008
IN 1998-DE342	A	19980211
US 1998-80433P	P	19980402
WO 2000-US3559	W	20000211

AB The invention relates to the use of peptides individually or in combination, for treating and/or preventing angiogenesis. It also relates to the use of peptide analogs or a combination of peptides referred to as MuJ-7 as anticancer drugs in restricting tumor growth and spread by inhibiting tumor angiogenesis. MuJ-7, in addn. inhibits metastasis through its antiangiogenic activity in all cancers. The invention also relates to a pharmaceutical compn. contg. either individual peptides or in combination, and methods of treatment of human beings and animals for curing and/or preventing angiogenesis.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 4 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN

ACCESSION NUMBER: 2001:296820 BIOSIS

DOCUMENT NUMBER: PREV200100296820

TITLE: Drug for the treatment of cancer.

AUTHOR(S): Mukherjee, Ram (1); ***Jaggi, Manu***

CORPORATE SOURCE: (1) New Delhi India
ASSIGNEE: National Institute of Immunology, New Delhi, India

PATENT INFORMATION: US 6156725 December 05, 2000

SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Dec. 5, 2000) Vol. 1241, No. 1, pp. No Pagination. e-file.
ISSN: 0098-1133.

DOCUMENT TYPE: Patent

LANGUAGE: English

AB A pharmaceutical composition useful for killing or inhibiting multiplication of cancer cells. It is expected that the pharmaceutical composition will be useful in preventing, inhibiting, or modulating the hypersecretion of VIP, somatostatin, ***bombesin*** , Substance P, or a combination of VIP, somatostatin, ***bombesin*** , or Substance P. The composition may suitably comprise, consist of, or consist essentially of a therapeutically effective combination of peptide analogs of somatostatin, VIP, ***bombesin*** , and Substance P. Also provided is a method of treatment for humans or other animals suffering from cancer, the method comprising administering a therapeutically effective dose of the pharmaceutical composition so as to kill or inhibit the multiplication of cancer cells. The method of treatment may be particularly useful in the treatment of cancers of the colon and rectum. Also provided is a method of treatment for humans or animals having hypersecretion or modulation of VIP, somatostatin, ***bombesin*** , Substance P, or a combination of VIP, somatostatin, ***bombesin*** , or Substance P.

=> d his

(FILE 'HOME' ENTERED AT 12:32:03 ON 17 AUG 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 12:32:27 ON 17 AUG 2003

L1	21051	S BOMBESIN
L2	0	S DIALKLYATED AMINO ACID
L3	11225	S AMINOISOBUTYRIC ACID
L4	7	S DIETHYL GLYCINE
L5	7	S DI-N-PROPYL GLYCINE
L6	592	S L1 (W) (ANALOG OR DERIVATIVE)
L7	1962	S L1 (P) (ANALOG OR DERIVATIVE)
L8	3	S L7 (P) (L3 OR L4 OR L5)
L9	1	DUPLICATE REMOVE L8 (2 DUPLICATES REMOVED)
L10	0	S BURMAN ANAND/AU
L11	31	S PRASAD SUDHANAND/AU
L12	26	S JAGGI MANU/AU
L13	26	S SINGH ANU/AU
L14	6	S MATHUR ARCHNA/AU
L15	0	S MAUKHERJEE RAMA/AU
L16	64	S MUKHERJEE RAMA/AU
L17	116	S L11 OR L12 OR L13 OR L14 OR L16
L18	4	S L17 AND L1
L19	4	DUPLICATE REMOVE L18 (0 DUPLICATES REMOVED)

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	58.86	59.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.95	-1.95

STN INTERNATIONAL LOGOFF AT 12:40:20 ON 17 AUG 2003